Recent 8-K filings for VCYT

• May 5, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Veracyte Q1 2026 revenue $139.1M (+21% YoY); GAAP net income $28.7M, adj. EBITDA $42.8M

  Total revenue $139.1M (+21% YoY); testing revenue $135.1M (+26% YoY).

• March 16, 2026, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Veracyte appoints Kevin Haas as Chief Development & Technology Officer, effective March 24, 2026

  Dr. Kevin Haas, formerly CTO of Myriad Genetics (NASDAQ: MYGN), joins as Chief Development and Technology Officer.

• February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Veracyte Q4 revenue $140.6M (+19% YoY); GAAP net income $41.1M, generates $52.6M operating cash

  Q4 total revenue $140.6M (+19% YoY); testing revenue $135.8M (+21%); total volume 48,019 tests (+16%).

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Veracyte prelim Q4 rev $138M-$140M (+16-18% YoY); guides FY26 rev $570M-$582M

  FY2025 total revenue $515M-$517M (+16% YoY); testing revenue $491M-$493M.

• November 4, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Veracyte Q3 revenue up 14% to $131.9M, raises FY guidance; adjusted EBITDA margin 30%

  Total revenue $131.9M (+14% YoY); testing rev $127.8M (+17%); GAAP net income $19.1M.

• August 6, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Veracyte Q2 revenue $130.2M (+14% YoY); raises testing revenue guidance

  Total revenue of $130.2M (+14% YoY); testing revenue of $122.3M (+14%).

• June 18, 2025, 7:59 PM ET other material materiality 0.30 neutral item 5.02item 5.07item 9.01

  VCYT shareholders approve 2.5M share equity plan increase, elect all directors

  Stockholders approved 2023 Plan Amendment to increase shares reserved by 2,500,000 (For: 50.6M, Against: 19.1M).

• May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Veracyte Q1 2025 revenue $114.5M (+18% YoY); net income $7.0M, Decipher revenue up 33%

  Total revenue $114.5M (+18% YoY); testing revenue $107.3M (+19%); total test volume 40,655 (+22%).

• February 24, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Veracyte Q4 revenue $118.6M (+21%), net income $5.1M vs. loss a year ago

  Q4 total revenue $118.6M (+21%), testing revenue $112.2M (+24%), testing volume +25% to 39,107 tests.

• November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Veracyte Q3 revenue $115.9M (+29% YoY), net income $15.2M

  Testing revenue $109.5M (+34%); total testing volume 36,792 (+24%); total tests 39,032 (+20%).

• September 4, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change ×2

  Veracyte appoints Tom Miller, Ph.D. and Brent Shafer to Board of Directors

  Appointments effective September 3, 2024; terms until 2025 annual meeting or successor.

• August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Veracyte Q2 revenue $114.4M (+27% YoY); net income $5.7M; record test volumes

  Total revenue $114.4M (+27% YoY); testing revenue +31%; test volume 39,023 (+23%).

• June 13, 2024, 7:59 PM ET regulatory materiality 0.60 neutral item 5.02item 5.07item 9.01

  Veracyte stockholders approve 5M share increase under 2023 equity plan

  Annual meeting held June 12, 2024; all four proposals passed.

• May 7, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Veracyte Q1 revenue $96.8M (+17%), testing revenue +25%, net loss narrows 77%

  Total revenue $96.8M (up 17% YoY); testing revenue $90.3M (up 25%) led by Decipher Prostate and Afirma.

• April 17, 2024, 7:59 PM ET M&A materiality 0.70 neutral item 9.01

  Veracyte completes C2i acquisition for up to $95M stock; C2i had $36M loss, $78.6M debt

  Acquisition closed Feb 5, 2024; total consideration up to $95M in Veracyte common stock.

• March 22, 2024, 7:59 PM ET other materiality 0.20 neutral item 8.01item 9.01

  Veracyte registers 1,016,965 shares for resale relating to C2i Genomics acquisition

  Filed prospectus supplement to register 1,016,965 shares of common stock for resale.

• February 29, 2024, 6:59 PM ET other material materiality 0.20 neutral item 8.01item 9.01

  Veracyte registers 1.68M shares for resale related to C2i Genomics acquisition

  Filed prospectus supplement to register up to 1,681,384 shares of common stock for resale.

• February 22, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Veracyte Q4 revenue $98.2M (+22% YoY); full-year $361.1M (+22%)

  Q4 2023 revenue $98.2M, up 22% YoY; testing revenue $90.4M (+29%).

• February 13, 2024, 6:59 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

  John L. Bishop to retire from Veracyte board at 2024 annual meeting

  John L. Bishop informed the board he will retire and not stand for reelection at the 2024 annual meeting.

• February 6, 2024, 6:59 PM ET M&A materiality 0.70 neutral item 2.01item 9.01item 3.02 ◈ M&A Transactions

  Veracyte completes $70M acquisition of C2i Genomics; milestone payments up to $25M

  Purchase price of $70M paid to C2i Genomics securityholders, subject to customary adjustments.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event earnings

11 positive 0 negative 9 neutral

source · VCYT on sec.gov